表2. 影响多发性骨髓瘤患者生存的单因素和多因素回归分析.
影响因素 | 无进展生存 |
总生存 |
||||||
单因素分析 |
多因素分析 |
单因素分析 |
多因素分析 |
|||||
HR(95% CI) | P值 | HR(95% CI) | P值 | HR(95% CI) | P值 | HR(95% CI) | P值 | |
男性 | 1.04(0.78~1.38) | 0.805 | 1.18(0.80~1.75) | 0.408 | ||||
年龄≥65岁 | 1.27(0.94~1.70) | 0.115 | 1.74(1.18~2.58) | 0.005 | 1.21(0.80~1.82) | 0.372 | ||
DS分期Ⅲ级 | 1.17(0.79~1.73) | 0.428 | 0.86(0.52~1.42) | 0.556 | ||||
ISS分期Ⅲ级 | 1.36(1.01~1.82) | 0.040 | 0.88(0.48~1.61) | 0.675 | 1.87(1.24~2.81) | 0.003 | 1.08(0.50~2.34) | 0.854 |
R-ISS分期Ⅲ级 | 1.21(0.88~1.68) | 0.242 | 1.47(0.97~2.24) | 0.072 | ||||
髓外病变 | 1.45(1.02~2.05) | 0.038 | 1.54(1.08~2.19) | 0.018 | 1.41(0.89~2.23) | 0.138 | ||
骨髓浆细胞比例≥30% | 1.11(0.83~1.48) | 0.484 | 1.06(0.72~1.57) | 0.769 | ||||
血红蛋白<100 g/L | 0.93(0.68~1.28) | 0.675 | 1.04(0.67~1.59) | 0.874 | ||||
白蛋白<35 g/L | 0.80(0.59~1.07) | 0.131 | 0.92(0.61~1.37) | 0.668 | ||||
肌酐≥177 µmol/L | 1.37(0.99~1.90) | 0.055 | 1.57(1.03~2.39) | 0.036 | 1.14(0.70~1.86) | 0.594 | ||
血清钙>2.65 mmol/L | 1.43(1.03~2.01) | 0.035 | 1.32(0.93~1.88) | 0.126 | 1.85(1.21~2.82) | 0.005 | 1.54(0.98~2.43) | 0.062 |
乳酸脱氢酶≥220 U/L | 1.82(1.22~2.72) | 0.004 | 1.50(1.00~2.26) | 0.053 | 3.14(1.95~5.07) | <0.001 | 2.64(1.62~4.31) | <0.001 |
β2微球蛋白≥5.5 mg/L | 1.39(1.04~1.86) | 0.026 | 1.33(0.73~2.40) | 0.352 | 1.85(1.23~2.76) | 0.003 | 1.25(0.59~2.65) | 0.556 |
HRCA≥2种 | 1.34(1.09~1.65) | 0.006 | 1.42(1.15~1.74) | 0.001 | 1.62(1.22~2.14) | 0.001 | 1.61(1.22~2.15) | 0.001 |
以硼替佐米和(或)来那度胺为基础的诱导治疗方案 | 0.92(0.68~1.24) | 0.573 | 0.96(0.64~1.43) | 0.837 | ||||
自体造血干细胞移植 | 0.32(0.19~0.54) | <0.001 | 0.34(0.20~0.56) | <0.001 | 0.22(0.09~0.54) | 0.001 | 0.27(0.11~0.67) | 0.005 |
注:HRCA:高危细胞遗传学异常